<DOC>
	<DOCNO>NCT00594555</DOCNO>
	<brief_summary>The purpose study evaluate safety combine chemotherapy treatment ( CLAG regimen ) Imatinib Mesylate ( Gleevec ) patient AML .</brief_summary>
	<brief_title>A Study Evaluating Effects CLAG With Gleevec Refractory Relapsed Acute Myeloid Leukemia</brief_title>
	<detailed_description>In relapse resistant acute myeloid leukemia ( type blood cancer immature blood cell increase , block normal blood cell production ) standard therapy exit . Response rate similar different chemotherapy treatment . Allogenic stem cell transplant remain curative option The purpose study evaluate safety combine chemotherapy treatment ( CLAG regimen ) Imatinib Mesylate ( Gleevec ) . The CLAG regimen combination chemotherapy drug cladribine cytarabine , well , neupogen increase white blood count . Imatinib Mesylate believe work interfere abnormal protein block tell body keep make abnormal white blood cell . Imatinib Mesylate approve FDA treatment chronic myeloid leukemia ( CML ) type acute lymphoblastic leukemia ( ALL ) . Its use combination CLAG regimen consider experimental treatment Acute Myeloid Leukemia / CML blast crisis The goal study find effect ( good bad ) Imatinib Mesylate ( Gleevec ) combine chemotherapy ( CLAG regimen ) acute myeloid leukemia .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Cladribine</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Inclusion Criteria Men Women ethnic group whose age ≥ 18 year old . Diagnosis AML CML blast crisis , accord WHO criterion , except acute promyelocytic leukemia AMLM3 FAB subgroup . Refractory Relapsed AML . Refractory AML define failure achieve CR 2 cycle induction chemotherapy persistent ( &gt; 40 % ) bone marrow blast one cycle chemotherapy induction . Relapsed AML define evidence disease recurrence achieve CR . Early relapse define occur within 12 month late relapse defines occur 12 month . ECOG performance status 0 1 . Patients must sign write informed consent . Females childbearing potential must pregnant actively nursing child . They must negative pregnancy test 7 day initiation study drug administration . Postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential . Male female reproductive potential must agree employ effective barrier method birth control throughout duration trial 3 month follow study medication discontinuation . Exclusion Criteria Abnormal Kidney Functions : creatinine ≥2.5mg/dL ; creatinine 2.02.5 , patient GFR measure dose Cytarabine may adjust accordingly . Abnormal Liver Functions : Bilirubin .2mg/dL , transaminases ( AST/ALT ) 2.5 time institutional upper limit normal ( IULN ) Systemic active infection , unless control active therapy . Patients Grade III/IV cardiac problem define New York Heart Association Criteria ( i.e. , congestive heart failure , myocardial infarction within 6 month study ) , EF 30 % . Patient know chronic liver disease ( i.e. , chronic active hepatitis cirrhosis ) . Patient known diagnosis human immunodeficiency virus ( HIV ) infection . History curatively untreated malignancy , except nonmelanotic skin cancer . Patients receive investigational agent within 1 month study entry . History allergic reaction attribute compound similar chemical biologic composition Gleevec component CLAG regimen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Blood disease , bone marrow</keyword>
	<keyword>AML</keyword>
	<keyword>CML , Blast Crisis</keyword>
</DOC>